ClinicalTrials.gg
CompletedNCT05126901FORTISUpdated Nov 10, 2025Results posted

Evaluate the Safety and Efficacy of Ferric Maltol Oral Suspension vs. Ferrous Sulfate Oral Liquid in Children and Adolescents Aged 2 to 17 Years With Iron-deficiency Anaemia, With a Single Arm Study in Infants Aged 1 Month to Less Than 2 Years

A Phase 3 interventional study of Ferric Maltol and Ferrous sulfate in Anemia and Iron-deficiency, sponsored by Shield Therapeutics. Completed at 23 sites in 3 countries. Open to participants aged 1 Month to 17 Years. Per ClinicalTrials.gov, last updated 2025-11-10.

Sponsored by Shield Therapeutics · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
1 Month to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 464 studies in Anemia with a site in United States — 38 open to participants now, 58 under way, 18 of them phase 3. Anemia · United States.

Enrollment
204th of 395
65 · median 72
Started
2021
with 15 others
Phase 3
114 of 464
5 open now
Registered
402nd of 464
by date

Among the 464 studies in Anemia with a site in United States, this one is the 204th largest by enrollment of the 395 interventional ones that give a count, is one of 16 that started in 2021, is one of 114 in phase 3, and was the 402nd registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

38 of the 464 studies in Anemia with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 1 Month to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 464 studies in Anemia with a site in United States, or all of them as a file.
02

Study summary

The objective of the study is to compare the safety and gastrointestinal tolerability of ferric maltol oral suspension and ferrous sulfate oral liquid in children and adolescents aged 2 years to 17 years, and assess the safety and tolerability of ferric maltol oral suspension in children 1 month to less than 2 years, in the treatment of iron deficiency anaemia during the 12 weeks treatment period.

Read the detailed description

The study is a randomised, Open-label, Active-controlled, Multicentre, Comparative Study to Evaluate the Safety and Efficacy of Ferric Maltol (Iron (III)-Maltol Complex) (ST10) Oral Suspension Compared to Ferrous Sulfate Oral Liquid in Children and Adolescents Aged 2 to 17 Years With Iron-deficiency Anaemia, Incorporating a Single Arm Study in Infants Aged 1 Month to Less Than 2 Years.

Approximately 110 male and female children from 1 month to 17 years of age, with iron deficiency anaemia. If less than 91 subjects in total have been randomized when 32 ferric maltol subjects have completed, then an interim analysis will be conducted.

Subjects aged 2 to 17 years will be 1:1 randomised to ferric maltol and ferrous sulfate, with 49 subjects in each arm. Subjects then will be further divided into 2 age groups: 2 yrs - 9 yrs and 10 yrs -17 yrs. A minimum of 18 subjects must be recruited into the 2 yrs - 9 yrs and 10 yrs - 17 yrs age groups and a minimum of 25% of either sex must be recruited.

A maximum of 12 subjects will be recruited in the 1 month to less than 2 years age group. They will only be assigned to the ferric maltol group, once there is evidence of absorption, of serum iron and elimination of maltol from the Pre-assignment PK samples by showing urine maltol return to baseline, or to a low level, confirming no accumulation of maltol or maltol glucuronide, they will continue on to the 12 weeks treatment phase.

Design: The study will comprise of the following stages:

  • Screening: within 14 days prior to randomisation for each subject
  • Pre-assignment PK phase: only applicable for subjects aged 1 month to less than 2 years. Up to 21 days from Screening.
  • Randomised treatment: 12 weeks open label treatment
  • Assigned treatment phase 12 weeks open label treatment for ferric maltol children aged 1 month to less than 2 years
  • End of study: Week 12 visit
  • Post-treatment safety follow-up: 10-14 days following study completion of the treatment period or premature discontinuation

Investigational Product Product: Ferric maltol oral suspension: oral suspension containing 30 mg elemental iron, in the form of 231.5 mg ferric maltol, in 5 ml suspension.

Ferric maltol oral suspension will be taken every morning and evening at least 30 minutes after a meal. Dosing will be supervised by the parent/legal guardian for children/adolescents throughout the treatment period and recorded on a dosing diary.

Ferric maltol bottles will be labelled for clinical trials use and each bottle will have a unique bottle number which will be utilised in the randomisation procedure.

A final eligibility evaluation must be conducted immediately prior to randomisation.

Reference safety information will be the Investigator Brochure.

Comparator therapy: Ferrous sulfate 125 mg/ml (25 mg/ml elemental iron) oral liquid or equivalent dose will be administered under this protocol. Dosing will be supervised by the parent/legal guardian for children/adolescents throughout the treatment period and recorded on a dosing diary.

Reference safety information will be the currently approved summary of product characteristics.

Statistical methods:

Safety and gastrointestinal tolerability will be compared between ferric maltol oral suspension and ferrous sulfate oral liquid via summaries of treatment emergent adverse events (TEAEs), treatment emergent serious AEs (TESAEs) and treatment-emergent AEs (TEAEs) leading to premature discontinuation of study drug.

Efficacy of ferric maltol will be assessed via the change in Hb concentration from baseline to week 12. If no interim analysis is conducted it will be based on a 95% two-sided confidence interval; If an interim analysis is conducted, a Pocock spending function will be used; the interim analysis will be based on a (100 - 3.45)% two sided confidence interval; if the study does not stop after the interim analysis, the final analysis will be based on a (100 - 2.57)% two sided confidence interval.

For the PK analysis, all analytes in serum will be summarised per PK day, for children and adolescents aged 1 month to 17 years receiving ferric maltol.

In addition, all analytes in urine will be summarised per PK day, for children aged 1 month to less than 2 years.

Full details of the statistical analysis, including the analysis of PK endpoints, will be specified in the statistical analysis plan (SAP).

03

Conditions studied

  • Anemia
  • Iron-deficiency

Keywords

  • Anemia
  • Iron-Deficiency
04

Who can participate

Ages eligible
1 Month to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient is willing and able to comply with the study requirements and to provide written . In the case of patients under the age of legal consent, the legal guardian(s) must provide informed consent and the patient should provide assent per local and national requirements.
  2. Age ≥1 month and ≤17 years at the time of informed consent
  3. Subjects must have iron deficiency anaemia defined by the following criteria, as measured by the central laboratory at the screening visit

thresholds define anaemia by age and gender:

Children (1 m - \< 5 yrs) \<11.0 g/dl Children (5 yrs - \< 12 yrs) \<11.5 g/dl Children (12 yrs) \<12.0 g/dl Female child (≥13 yrs) \<12.0 g/dl Male child (≥13 yrs) \<13.0 g/dl and

Ferritin thresholds define anaemia by:

ferritin \<30 µg/L, or ferritin \<50 µg/L with transferrin saturation (TSAT) \<20%, 4. Female subjects of must agree to use a highly effective method of (which includes complete abstinence) until study completion and for at least 4 weeks following their final study visit. Highly effective contraception is defined as a method which results in a low failure rate, i.e., less than 1% per year when used consistently and correctly, such as implants, injectables, some intrauterine contraceptive devices (IUDs), a vasectomised partner and oral contraceptive medications.

The need for contraception and compliance with contraception requirements will be assessed at every visit for adolescent patients, and urine pregnancy testing will be performed at each visit for female subjects of childbearing potential.

Exclusion criteria

Exclusion Criteria:

  1. Subject with anaemia due to any cause other than iron deficiency, including, but not limited to,

    a. Untreated or untreatable severe malabsorption syndrome

  2. Subjects who have received prior to Screening:

    1. Within 28 days intramuscular or intravenous (IV) injection or administration of depot iron preparation.
    2. Within 7 days single agent iron preparations and during the study.
    3. Within 12 weeks of blood transfusion or is scheduled to have blood transfusion or donation during the study period
    4. Within 28 days erythropoiesis stimulating agents and during the study period
    5. Within 14 days COVID-19 vaccination
  3. Subjects with vitamin B12 or folic acid deficiency as determined by the central laboratory screening results. Subjects may start vitamin B12 or folate replacement and rescreen after at least 2 weeks.
  4. Has concomitant disease that would significantly compromise iron absorption or absorbed iron utilization such as swallowing disorders and/or extensive small bowel resection.
  5. History of active peptic ulcer
  6. Has chronic renal disease ( \<60 mL/min/m2), as assessed at Screening based on serum creatinine.
  7. Known or allergy to either the active substance or of ferric maltol or ferrous sulfate.
  8. Has a known for treatment with iron preparations, e.g. haemochromatosis, chronic haemolytic disease, sideroblastic anaemia, thalassemia, or lead intoxication induced anaemia.
  9. Impaired liver function as indicated by (ALT) or aspartate transaminase (AST)>2.0 times upper normal limit as measured at the Screening visit.
  10. Active acute inflammatory disease, including IBD flare or disease exacerbation, which in the opinion of the Investigator, is .
  11. Active chronic or acute infectious diseases requiring antibiotic treatment.
  12. Pregnant or breast feeding.
  13. Concomitant medical conditions with extensive active bleeding, other than menstrual cycles; subjects who suffer from menorrhagia may be included at the Investigator's discretion.
  14. Scheduled or expected hospitalisation and/or surgery during the course of the study
  15. Participation in any other interventional clinical study within 28 days prior to Screening.
  16. Diagnosed to be COVID-19 positive by (SARS-CoV-2-RT-PCR positive) within 28 days prior to screening.
  17. Cardiovascular, liver, renal, hematologic, psychiatric, neurologic, gastrointestinal, immunologic, endocrine, metabolic, respiratory or central nervous system disease that, in the opinion of the Investigator, may adversely affect the safety of the subject and/or objectives of the study drug or severely limit the lifespan of the subject.
  18. Any other unspecified reason that, in the opinion of the Investigator or the Sponsor make the subject unsuitable for enrolment.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    1 month to 2 year old subjects (infants)

    Subjects aged 1 month to less than 2 years will enter a Pre-assignment phase: baseline urine samples are collected and subjects will take a single dose of 0.1 ml/kg ferric maltol suspension. Further 3 samples up to 12h will be taken. Subjects showing evidence of absorption, metabolism and elimination of maltol will enter the treatment phase and be assigned to the ferric maltol arm. The first 6 subjects screened will perform the pre-assignment PK phase. After review by the investigator, and medical monitors , if Maltol Glucuronide is shown to be adequately eliminated, timepoint 20-24 hrs (+ 4hrs) will not be performed on subsequent subjects. Subjects will be assigned to receive ferric maltol oral suspension and start the 0.1 ml/kg BID dose on V2 and continue for 7-10 days. On V3 they will perform the same PK assessments as on Pre-assignment PK visit.

    Drug: Ferric Maltol

  • Experimental
    2 to 17 year old subjects - Ferric Maltol

    Subjects aged 2-17 will be randomised 1:1 to receive ferric maltol oral suspension or ferrous sulfate oral liquid. The first 12 subjects randomised to ferric maltol in each age sub-group (2 - 9 yrs, 10 - 17 yrs respectively) will enter a PK phase with 2 PK days. Following PK Day 2 subjects will continue until Week 12. Once the 18 subjects in each age subgroup have finished their PK visits, they will continue until week 12. Ferrous sulfate 125 mg/ml (25 mg elemental iron) or equivalent dose will be used for all children/adolescents. To maximise the iron replenishment for subjects within this group as well; aged 2 - 17 yrs will be dosed 6 mg/kg to the maximum of 4 ml BID. Subjects randomised to ferrous sulfate oral liquid will not need to complete the PK period.

    Drug: Ferric Maltol

  • Active comparator
    2 to 17 year old subjects - Ferrous Sulfate

    Subjects aged 2-17 will be randomised 1:1 to receive ferric maltol oral suspension or ferrous sulfate oral liquid. Ferrous sulfate 125 mg/ml (25 mg elemental iron) or equivalent dose will be used for all children/adolescents. To maximise the iron replenishment for subjects within this group as well; aged 2 - 17 yrs will be dosed 6 mg/kg to the maximum of 4 ml BID. Subjects randomised to ferrous sulfate oral liquid will not need to complete the PK period.

    Drug: Ferrous sulfate

Interventions

  • Ferric maltol oral suspension: 150 ml amber glass bottle with graduated syringe and adaptor. Oral suspension containing 30 mg elemental iron, in the form of 231.5 mg ferric maltol, in 5 ml suspension Study dosage: The dose of ferric maltol oral suspension that will be administered for children aged 1 month to \< 2 yrs: 0.1 ml/kg BID, 2 to - 11 yrs: 2.5 ml BID, 12-17 yrs: 5 ml BID.

    Also known as: Feraccru, Ferric Trimaltol, ST10, ST10-01

  • Ferrous sulfate 125 mg/ml (25 mg/ml elemental iron) oral liquid : 15 ml glass bottle. Study dosage: For ferrous sulfate oral liquid, the dose administered will be for children and adolescents aged 2 years to 17 yrs: 6 mg/kg to the maximum of 4 ml BID.

06

What researchers measure

Primary outcomes

  1. Change in Hemoglobin Concentration

    The change in Hb concentration from baseline to Week 12 is summarized based on the mITT Population for each treatment group using descriptive statistics summarized by mean, standard deviation, median, and range (minimum and maximum). The Randomized/ITT Population is defined as all patients who were randomized/assigned to treatment arms. The mITT Population is defined as all patients in the ITT Population who received at least 1 treatment dose.

    Time frame: From baseline to week 12.

Secondary outcomes

  1. Changes in Ferritin Concentration

    Changes in ferritin concentration from baseline to week 12 summarised based on the mITT Population for each treatment group. The Randomized/ITT Population is defined as all patients who were randomized/assigned to treatment arms. The mITT Population is defined as all patients in the ITT Population who received at least 1 treatment dose.

    Time frame: From baseline to week 12.

  2. Change in Iron Concentration

    Change in iron concentration from baseline to week 12 summarized based on the mITT Population for each treatment group. The Randomized/ITT Population is defined as all patients who were randomized/assigned to treatment arms. The mITT Population is defined as all patients in the ITT Population who received at least 1 treatment dose.

    Time frame: From baseline to week 12.

  3. Change in the Percentage of Transferrin Saturation

    Change from baseline to Day 84 summarized based on the mITT Population for each treatment group. The Randomized/ITT Population is defined as all patients who were randomized/assigned to treatment arms. The mITT Population is defined as all patients in the ITT Population who received at least 1 treatment dose.

    Time frame: From baseline to week 12.

  4. Cmax for Plasma Maltol Glucuronide

    Measured maximum plasma concentration (Cmax) (ng/mL) for plasma maltol glucuronide after a single dose of ferric maltol oral suspension on Visit 2 (PK Day 1) and after twice daily administrations for at least 6 days, on Visit 3 (PK Day 2) after a single morning dose. Because of the limitations of PK sampling in the pediatric patient population, data from multiple patients in the same treatment and age group had to be combined, using the naïve pooled approach, to achieve a complete set of observations over time for PK analysis. The data did not support PK parameters generation using noncompartmental analysis (NCA) without combining patients. Using validated PK software WinNonlin, the 'sparse sampling' option was utilized to treat the data as one virtual subject and thus the resulting data did not support reliable error estimates of the PK parameters.

    Time frame: PK parameters assessed at Day 1 (Visit 2) and Day 7-10 (Visit 3).

  5. Tmax for Plasma Maltol Glucuronide

    Time to maximum plasma concentration (Tmax) (h) for plasma maltol glucuronide after a single dose of ferric maltol oral suspension on Visit 2 (PK Day 1) and after twice daily administrations for at least 6 days, on Visit 3 (PK Day 2) after a single morning dose. Because of the limitations of PK sampling in the pediatric patient population, data from multiple patients in the same treatment and age group had to be combined, using the naïve pooled approach, to achieve a complete set of observations over time for PK analysis. The data did not support PK parameters generation using noncompartmental analysis (NCA) without combining patients. Using validated PK software WinNonlin, the 'sparse sampling' option was utilized to treat the data as one virtual subject and thus the resulting data did not support reliable error estimates of the PK parameters.

    Time frame: PK parameters assessed at Day 1 (Visit 2) and Day 7-10 (Visit 3).

  6. AUC0-t for Plasma Maltol Glucuronide

    Area under the plasma concentration-time curve from pre-dose (time 0) to the time of last quantifiable plasma concentration for plasma maltol glucuronide (AUC0-t) (hxng/mL) after a single dose of ferric maltol oral suspension on Visit 2 (PK Day 1) and after twice daily administrations for at least 6 days, on Visit 3 (PK Day 2) after a single morning dose. Because of the limitations of PK sampling in the pediatric patient population, data from multiple patients in the same treatment and age group had to be combined, using the naïve pooled approach, to achieve a complete set of observations over time for PK analysis. The data did not support PK parameters generation using noncompartmental analysis (NCA) without combining patients. Using validated PK software WinNonlin, the 'sparse sampling' option was utilized to treat the data as one virtual subject and thus the resulting data did not support reliable error estimates of the PK parameters.

    Time frame: PK parameters assessed at Day 1 (Visit 2) and Day 7-10 (Visit 3).

  7. Cmax for Baseline Corrected Serum Iron

    Measured maximum plasma concentration (Cmax) (μg/dL) for baseline corrected serum iron after a single dose of ferric maltol oral suspension on Visit 2 (PK Day 1) and after twice daily administrations for at least 6 days, on Visit 3 (PK Day 2) after a single morning dose. Because of the limitations of PK sampling in the pediatric patient population, data from multiple patients in the same treatment and age group had to be combined, using the naïve pooled approach, to achieve a complete set of observations over time for PK analysis. The data did not support PK parameters generation using noncompartmental analysis (NCA) without combining patients. Using validated PK software WinNonlin, the 'sparse sampling' option was utilized to treat the data as one virtual subject and thus the resulting data did not support reliable error estimates of the PK parameters.

    Time frame: PK parameters assessed at Day 1 (Visit 2) and Day 7-10 (Visit 3).

  8. Tmax for Baseline Corrected Serum Iron

    Time to maximum plasma concentration (Tmax) (h) for baseline corrected serum iron after a single dose of ferric maltol oral suspension on Visit 2 (PK Day 1) and after twice daily administrations for at least 6 days, on Visit 3 (PK Day 2) after a single morning dose. Because of the limitations of PK sampling in the pediatric patient population, data from multiple patients in the same treatment and age group had to be combined, using the naïve pooled approach, to achieve a complete set of observations over time for PK analysis. The data did not support PK parameters generation using noncompartmental analysis (NCA) without combining patients. Using validated PK software WinNonlin, the 'sparse sampling' option was utilized to treat the data as one virtual subject and thus the resulting data did not support reliable error estimates of the PK parameters.

    Time frame: PK parameters assessed at Day 1 (Visit 2) and Day 7-10 (Visit 3).

  9. AUC0-t for Baseline Corrected Serum Iron

    Area under the plasma concentration-time curve from pre-dose (time 0) to the time of last quantifiable plasma concentration for baseline corrected serum iron (AUC0-t) (hxng/mL) after a single dose of ferric maltol oral suspension on Visit 2 (PK Day 1) and after twice daily administrations for at least 6 days, on Visit 3 (PK Day 2) after a single morning dose. Because of the limitations of PK sampling in the pediatric patient population, data from multiple patients in the same treatment and age group had to be combined, using the naïve pooled approach, to achieve a complete set of observations over time for PK analysis. The data did not support PK parameters generation using noncompartmental analysis (NCA) without combining patients. Using validated PK software WinNonlin, the 'sparse sampling' option was utilized to treat the data as one virtual subject and thus the resulting data did not support reliable error estimates of the PK parameters.

    Time frame: PK parameters assessed at Day 1 (Visit 2) and Day 7-10 (Visit 3).

07

Results

Posted Nov 10, 2025

Participant flow

This was a multicenter study with a total of 23 clinical sites located in the United States(including Puerto Rico) and United Kingdom. A total of 65 patients were enrolled in the study.

Participant flow — Overall Study
MilestoneFerric Maltol AssignedFerric Maltol RandomizedFerrous Sulfate Randomized
Started43130
Completed32825
Not completed135
Withdrew: Withdrawal by subject114
Withdrew: Adverse event001
Withdrew: Lost to follow-up020

Outcome measures

PrimaryChange in Hemoglobin Concentration

The change in Hb concentration from baseline to Week 12 is summarized based on the mITT Population for each treatment group using descriptive statistics summarized by mean, standard deviation, median, and range (minimum and maximum). The Randomized/ITT Population is defined as all patients who were randomized/assigned to treatment arms. The mITT Population is defined as all patients in the ITT Population who received at least 1 treatment dose.

Time frame:
From baseline to week 12.
Reported as:
Mean · g/L
Change in Hemoglobin Concentration
g/LmITT Ferric Maltol AssignedmITT Ferric MaltolmITT Ferrous Sulfate
Change in Hemoglobin Concentration17.7 ± 13.6112.5 ± 13.8911.5 ± 13.97
SecondaryChanges in Ferritin Concentration

Changes in ferritin concentration from baseline to week 12 summarised based on the mITT Population for each treatment group. The Randomized/ITT Population is defined as all patients who were randomized/assigned to treatment arms. The mITT Population is defined as all patients in the ITT Population who received at least 1 treatment dose.

Time frame:
From baseline to week 12.
Reported as:
Mean · μg/L
Changes in Ferritin Concentration
μg/LmITT Ferric Maltol AssignedmITT Ferric MaltolmITT Ferrous Sulfate
Changes in Ferritin Concentration6.3 ± 8.748.1 ± 11.0620.6 ± 30.97
SecondaryChange in Iron Concentration

Change in iron concentration from baseline to week 12 summarized based on the mITT Population for each treatment group. The Randomized/ITT Population is defined as all patients who were randomized/assigned to treatment arms. The mITT Population is defined as all patients in the ITT Population who received at least 1 treatment dose.

Time frame:
From baseline to week 12.
Reported as:
Mean · μmol/L
Change in Iron Concentration
μmol/LmITT Ferric Maltol AssignedmITT Ferric MaltolmITT Ferrous Sulfate
Change in Iron Concentration1.07 ± 0.5775.77 ± 8.5183.64 ± 8.911
SecondaryChange in the Percentage of Transferrin Saturation

Change from baseline to Day 84 summarized based on the mITT Population for each treatment group. The Randomized/ITT Population is defined as all patients who were randomized/assigned to treatment arms. The mITT Population is defined as all patients in the ITT Population who received at least 1 treatment dose.

Time frame:
From baseline to week 12.
Reported as:
Mean · Percentage of Transferrin Saturation
Change in the Percentage of Transferrin Saturation
Percentage of Transferrin SaturationmITT Ferric Maltol AssignedmITT Ferric MaltolmITT Ferrous Sulfate
Change in the Percentage of Transferrin Saturation2.0 ± 0.007.7 ± 10.146.5 ± 12.39
SecondaryCmax for Plasma Maltol Glucuronide

Measured maximum plasma concentration (Cmax) (ng/mL) for plasma maltol glucuronide after a single dose of ferric maltol oral suspension on Visit 2 (PK Day 1) and after twice daily administrations for at least 6 days, on Visit 3 (PK Day 2) after a single morning dose. Because of the limitations of PK sampling in the pediatric patient population, data from multiple patients in the same treatment and age group had to be combined, using the naïve pooled approach, to achieve a complete set of observations over time for PK analysis. The data did not support PK parameters generation using noncompartmental analysis (NCA) without combining patients. Using validated PK software WinNonlin, the 'sparse sampling' option was utilized to treat the data as one virtual subject and thus the resulting data did not support reliable error estimates of the PK parameters.

Time frame:
PK parameters assessed at Day 1 (Visit 2) and Day 7-10 (Visit 3).
Reported as:
Number · ng/mL
Cmax for Plasma Maltol Glucuronide
ng/mLPK Population Ferric Maltol 15mg (2-9 y) Day 1PK Population Ferric Maltol 15mg (10-17 y) Day 1PK Population Ferric Maltol 30mg (10-17 y) Day 1PK Population Ferric Maltol 15mg (2-9 y) Day 7-10PK Population Ferric Maltol 15mg (10-17 y) Day 7-10PK Population Ferric Maltol 30mg (10-17 y) Day 7-10
Cmax for Plasma Maltol Glucuronide4350 ± NA6810 ± NA6420 ± NA4250 ± NA5940 ± NA8160 ± NA
SecondaryTmax for Plasma Maltol Glucuronide

Time to maximum plasma concentration (Tmax) (h) for plasma maltol glucuronide after a single dose of ferric maltol oral suspension on Visit 2 (PK Day 1) and after twice daily administrations for at least 6 days, on Visit 3 (PK Day 2) after a single morning dose. Because of the limitations of PK sampling in the pediatric patient population, data from multiple patients in the same treatment and age group had to be combined, using the naïve pooled approach, to achieve a complete set of observations over time for PK analysis. The data did not support PK parameters generation using noncompartmental analysis (NCA) without combining patients. Using validated PK software WinNonlin, the 'sparse sampling' option was utilized to treat the data as one virtual subject and thus the resulting data did not support reliable error estimates of the PK parameters.

Time frame:
PK parameters assessed at Day 1 (Visit 2) and Day 7-10 (Visit 3).
Reported as:
Number · h
Tmax for Plasma Maltol Glucuronide
hPK Population Ferric Maltol 15mg (2-9 y) Day 1PK Population Ferric Maltol 15mg (10-17 y) Day 1PK Population Ferric Maltol 30mg (10-17 y) Day 1PK Population Ferric Maltol 15mg (2-9 y) Day 7-10PK Population Ferric Maltol 15mg (10-17 y) Day 7-10PK Population Ferric Maltol 30mg (10-17 y) Day 7-10
Tmax for Plasma Maltol Glucuronide1.00 ± NA2.13 ± NA0.52 ± NA0.98 ± NA2.78 ± NA3.63 ± NA
SecondaryAUC0-t for Plasma Maltol Glucuronide

Area under the plasma concentration-time curve from pre-dose (time 0) to the time of last quantifiable plasma concentration for plasma maltol glucuronide (AUC0-t) (hxng/mL) after a single dose of ferric maltol oral suspension on Visit 2 (PK Day 1) and after twice daily administrations for at least 6 days, on Visit 3 (PK Day 2) after a single morning dose. Because of the limitations of PK sampling in the pediatric patient population, data from multiple patients in the same treatment and age group had to be combined, using the naïve pooled approach, to achieve a complete set of observations over time for PK analysis. The data did not support PK parameters generation using noncompartmental analysis (NCA) without combining patients. Using validated PK software WinNonlin, the 'sparse sampling' option was utilized to treat the data as one virtual subject and thus the resulting data did not support reliable error estimates of the PK parameters.

Time frame:
PK parameters assessed at Day 1 (Visit 2) and Day 7-10 (Visit 3).
Reported as:
Number · hxng/mL
AUC0-t for Plasma Maltol Glucuronide
hxng/mLPK Population Ferric Maltol 15mg (2-9 y) Day 1 Subject analysisPK Population Ferric Maltol 15mg (10-17 y) Day 1PK Population Ferric Maltol 30mg (10-17 y) Day 1PK Population Ferric Maltol 15mg (2-9 y) Day 7-10PK Population Ferric Maltol 15mg (10-17 y) Day 7-10PK Population Ferric Maltol 30mg (10-17 y) Day 7-10
AUC0-t for Plasma Maltol Glucuronide7670 ± NA12000 ± NA14600 ± NA5900 ± NA8070 ± NA16700 ± NA
SecondaryCmax for Baseline Corrected Serum Iron

Measured maximum plasma concentration (Cmax) (μg/dL) for baseline corrected serum iron after a single dose of ferric maltol oral suspension on Visit 2 (PK Day 1) and after twice daily administrations for at least 6 days, on Visit 3 (PK Day 2) after a single morning dose. Because of the limitations of PK sampling in the pediatric patient population, data from multiple patients in the same treatment and age group had to be combined, using the naïve pooled approach, to achieve a complete set of observations over time for PK analysis. The data did not support PK parameters generation using noncompartmental analysis (NCA) without combining patients. Using validated PK software WinNonlin, the 'sparse sampling' option was utilized to treat the data as one virtual subject and thus the resulting data did not support reliable error estimates of the PK parameters.

Time frame:
PK parameters assessed at Day 1 (Visit 2) and Day 7-10 (Visit 3).
Reported as:
Number · μg/dL
Cmax for Baseline Corrected Serum Iron
μg/dLPK Population Ferric Maltol 15mg (2-9 y) Day 1PK Population Ferric Maltol 15mg (10-17 y) Day 1PK Population Ferric Maltol 30mg (10-17 y) Day 1PK Population Ferric Maltol 15mg (2-9 y) Day 7-10PK Population Ferric Maltol 15mg (10-17 y) Day 7-10PK Population Ferric Maltol 30mg (10-17 y) Day 7-10
Cmax for Baseline Corrected Serum Iron87.0 ± NA40.0 ± NA119 ± NA96.5 ± NA21.0 ± NA364 ± NA
SecondaryTmax for Baseline Corrected Serum Iron

Time to maximum plasma concentration (Tmax) (h) for baseline corrected serum iron after a single dose of ferric maltol oral suspension on Visit 2 (PK Day 1) and after twice daily administrations for at least 6 days, on Visit 3 (PK Day 2) after a single morning dose. Because of the limitations of PK sampling in the pediatric patient population, data from multiple patients in the same treatment and age group had to be combined, using the naïve pooled approach, to achieve a complete set of observations over time for PK analysis. The data did not support PK parameters generation using noncompartmental analysis (NCA) without combining patients. Using validated PK software WinNonlin, the 'sparse sampling' option was utilized to treat the data as one virtual subject and thus the resulting data did not support reliable error estimates of the PK parameters.

Time frame:
PK parameters assessed at Day 1 (Visit 2) and Day 7-10 (Visit 3).
Reported as:
Number · h
Tmax for Baseline Corrected Serum Iron
hPK Population Ferric Maltol 15mg (2-9 y) Day 1PK Population Ferric Maltol 15mg (10-17 y) Day 1PK Population Ferric Maltol 30mg (10-17 y) Day 1PK Population Ferric Maltol 15mg (2-9 y) Day 7-10PK Population Ferric Maltol 15mg (10-17 y) Day 7-10PK Population Ferric Maltol 30mg (10-17 y) Day 7-10
Tmax for Baseline Corrected Serum Iron2.37 ± NA2.13 ± NA2.00 ± NA2.10 ± NA2.78 ± NA6.63 ± NA
SecondaryAUC0-t for Baseline Corrected Serum Iron

Area under the plasma concentration-time curve from pre-dose (time 0) to the time of last quantifiable plasma concentration for baseline corrected serum iron (AUC0-t) (hxng/mL) after a single dose of ferric maltol oral suspension on Visit 2 (PK Day 1) and after twice daily administrations for at least 6 days, on Visit 3 (PK Day 2) after a single morning dose. Because of the limitations of PK sampling in the pediatric patient population, data from multiple patients in the same treatment and age group had to be combined, using the naïve pooled approach, to achieve a complete set of observations over time for PK analysis. The data did not support PK parameters generation using noncompartmental analysis (NCA) without combining patients. Using validated PK software WinNonlin, the 'sparse sampling' option was utilized to treat the data as one virtual subject and thus the resulting data did not support reliable error estimates of the PK parameters.

Time frame:
PK parameters assessed at Day 1 (Visit 2) and Day 7-10 (Visit 3).
Reported as:
Number · hxμg/dL
AUC0-t for Baseline Corrected Serum Iron
hxμg/dLPK Population Ferric Maltol 15mg (2-9 y) Day 1PK Population Ferric Maltol 15mg (10-17 y) Day 1PK Population Ferric Maltol 30mg (10-17 y) Day 1PK Population Ferric Maltol 15mg (2-9 y) Day 7-10PK Population Ferric Maltol 15mg (10-17 y) Day 7-10PK Population Ferric Maltol 30mg (10-17 y) Day 7-10
AUC0-t for Baseline Corrected Serum Iron64.4 ± NA60.1 ± NA374 ± NA100 ± NA1.93 ± NA1180 ± NA

Adverse events

Collected over During the 12-week treatment period and within 2 weeks after receiving the last dose of the study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ferric Maltol Assigned0/3 (0%)1/3 (33.3%)2/3 (66.7%)
Ferric Maltol Randomized0/31 (0%)0/31 (0%)4/31 (12.9%)
Ferrous Sulfate Randomized0/30 (0%)0/30 (0%)3/30 (10%)
Most frequent serious events
Most frequent serious events
EventFerric Maltol AssignedFerric Maltol RandomizedFerrous Sulfate Randomized
WheezingRespiratory, thoracic and mediastinal disorders1/30/310/30
Most frequent other events
Most frequent other events
EventFerric Maltol AssignedFerric Maltol RandomizedFerrous Sulfate Randomized
Iron deficiency anaemiaBlood and lymphatic system disorders1/30/310/30
DiarrhoeaGastrointestinal disorders1/31/310/30
TeethingGastrointestinal disorders1/30/310/30
CoughRespiratory, thoracic and mediastinal disorders1/31/310/30
ConjunctivitisInfections and infestations1/30/310/30
NauseaGastrointestinal disorders0/32/313/30
PyrexiaGeneral disorders0/32/310/30

Baseline characteristics

Age, Customized
Age, Customized(Participants)Ferric Maltol AssignedFerric Maltol RandomizedFerrous Sulfate RandomizedTotal
Preterm newborn infants (gestational age < 37 wks)0000
Newborns (0-27 days)0000
Infants and toddlers (28 days-23 months)4004
Children (2-11 years)0101121
Adolescents (12-17 years)0211940
Adults (18-64 years)0000
From 65-84 years0000
85 years and over0000
Sex: Female, Male
Sex: Female, Male(Participants)Ferric Maltol AssignedFerric Maltol RandomizedFerrous Sulfate RandomizedTotal
Female3232248
Male18817
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ferric Maltol AssignedFerric Maltol RandomizedFerrous Sulfate RandomizedTotal
Hispanic or Latino2131227
Not Hispanic or Latino1181837
Unknown or Not Reported1001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ferric Maltol AssignedFerric Maltol RandomizedFerrous Sulfate RandomizedTotal
American Indian or Alaska Native0000
Asian1337
Native Hawaiian or Other Pacific Islander0000
Black or African American091120
White1181635
More than one race0000
Unknown or Not Reported2103
08

Study locations

23 sites
  • The Center for Clinical Trials
    Saraland, Alabama 36571, United States
  • Homestead Research Institute
    Homestead, Florida 33030, United States
  • Kissimmee Clinical Research Corp
    Kissimmee, Florida 34743, United States
  • Miami Clinical Research
    Miami, Florida 33155, United States
  • Medical Research of Westcheste
    Miami, Florida 33165, United States
  • Eminent Clinical Research and Associates
    North Lauderdale, Florida 33068, United States
  • Clinical Research Prime
    Idaho Falls, Idaho 83404, United States
  • Sierra Clinical Research
    Las Vegas, Nevada 89106, United States
  • Levine Cancer Institute
    Charlotte, North Carolina 28204, United States
  • Penn State Hershey Children's Hospital
    Hershey, Pennsylvania 17033, United States
  • Hasbro Children's Hospital
    Providence, Rhode Island 02903, United States
  • BRCR Global Texas
    Edinburg, Texas 78539, United States
  • Zion Research
    Katy, Texas 77494, United States
  • MultiCare Health System Institute for Research and Innovation
    Tacoma, Washington 98405, United States
  • BRCR Global Puerto
    San Juan, 00907, Puerto Rico
  • Noah's Ark Children's Hospital for Wales
    Cardiff, CF14 4XW, United Kingdom
  • Royal Hospital for Sick Children - Edinburgh
    Edinburgh, EH16 4TJ, United Kingdom
  • Leicester Royal Infirmary
    Leicester, LE1 5WW, United Kingdom
  • Alder Hey Children's NHS Foundation Trust
    Liverpool, United Kingdom
  • King's College Hospital
    London, SE5 9RS, United Kingdom
  • Newham University Hospital
    London, United Kingdom
  • Royal Manchester Children's Hospital
    Manchester, M13 9WL, United Kingdom
  • Nottingham University Hospitals
    Nottingham, NG7 2UH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Jun 2024, 31 months.

Results were first posted in Nov 2025, 1 year 5 months after primary completion.

Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 31 months is above that.

Counting every sponsor, half of 150 studies reached it within 30 months; a quarter within 17 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2021
First posted
Nov 19, 2021
StartActual
Nov 3, 2021
Primary completionActual
Jun 9, 2024
CompletionActual
Jun 9, 2024
Results first posted
Nov 10, 2025
Last update
Nov 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05126901
Lead sponsor
Shield Therapeutics
Responsible party
Sponsor
First posted
Nov 19, 2021
Start date
Nov 3, 2021
Primary completion
Jun 9, 2024
Completion
Jun 9, 2024
Results posted
Nov 10, 2025
Last update
Nov 10, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric maltol

Start the discussion